Share LinkedIn Email Copy Link The layoffs will help extend the company’s cash runway from the second half of 2026 into 2028.Read more about this post on Biospace
EndPoints Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopesDecember 31, 2024
EndPoints Despite mixed data in Alzheimer’s agitation, Axsome will still seek FDA approvalDecember 30, 2024